HomeUncategorized
Uncategorized
Teva Pharmaceuticals and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease
Patient enrollment in the RELIEVE UCCD (ulcerative colitis and Crohn’s disease) Phase 2b trial has completed early due to significant acceleration in patient recruitment. As a result, Teva Pharmaceuticals and Sanofi now anticipate having topline results for both UC and CD in Q4 2024, and detailed results will be presented in a scientific forum in 2025. This adjustment replaces the previously planned interim analysis for the second half of 2024, which will not be conducted. Teva and Sanofi are collaborating to co-develop and co-commercialize duvakitug for moderate-to-severe UC and CD patients.
Press Release Policy for Medical Device News Magazine
Medical Device News Magazine | Press Release Policy
Send press releases to:
Pauline T. Mayer, Editor, mdnewsmagazine@infomeddnews.com
Helen Harrison, Assistant Editor, helen.h@infomeddnews.com
Send press releases to Medical Device...
Cookie Policy for Medical Device News Magazine
Please read this cookie policy (“cookie policy”, "policy") carefully before using Medical Device News Magazine website.
We have developed this cookie policy (the “Cookie Policy”)...
Cookie Policy – Please Read
MEDICAL DEVICE NEWS MAGAZINE COOKIE POLICY
Medical Device News Magazine uses cookies. Cookies are text files that are placed on your computer by websites you...
Recent News
MEDICAL DEVICES, TECHNOLOGIES, EQUIPMENT, SUPPLIES
Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants
"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."
MEDICAL DEVICES, TECHNOLOGIES, EQUIPMENT, SUPPLIES
Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting
This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.
MEDICAL DEVICES, TECHNOLOGIES, EQUIPMENT, SUPPLIES
Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution
“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”